Results 21 to 30 of about 284,051 (203)

Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study

Journal of Lipid Research, 1999
Heterozygous familial hypercholesterolemia (FH) is associated with a moderate decrease of plasma apoA-I and HDL-cholesterol levels. The aim of the study was to test the hypothesis that these abnormalities were related to an increase of HDL-apoA-I ...
Michel Krempf, K Ouguerram, P Benlian
exaly   +3 more sources

Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia. [PDF]

PLoS ONE, 2016
The role of plasma cholesterol in impairing arterial function and elasticity remains unclear. We evaluated arterial stiffness, measured locally in the common carotid artery by high-resolution echo-tracking, and aortic stiffness, using carotid-femoral ...
Alexandra I Ershova, Alexey N Meshkov, Tatyana A Rozhkova, Maria V Kalinina, Alexander D Deev, Anatoliy N Rogoza, Tatyana V Balakhonova, Sergey A Boytsov   +7 more
doaj   +4 more sources

Utilidad de la ecografía de alta resolución en la valoración de la aterosclerosis preclínica, riesgo cardiovascular y diagnóstico de la hipercolesterolemia familiar [PDF]

, 2006
[spa] La presente tesis valora la utilidad de la ecografía carotídea de alta resolución, como técnica diagnóstica incruenta, útil, validada, reproducible y de bajo coste que nos permite:1.
Junyent Priu, Mireia
core   +6 more sources

Aortic stiffness in young patients with heterozygous familial hypercholesterolemia

American Heart Journal, 1998
Dyslipidemia is a primary risk factor for the development of atherosclerosis. Aortic distensibility is an important determinant of left ventricular function and coronary blood flow whose possible alterations in patients with dyslipidemia have not been fully investigated.To assess the effect of dyslipidemia on the elastic properties of the aorta, we ...
Pitsavos, C, Toutouzas, K, Dernellis, J, Skoumas, J, Skoumbourdis, E, Stefanadis, C, Toutouzas, P   +6 more
core   +5 more sources

The genetics of familial hypercholesterolemia and emerging therapies

The Application of Clinical Genetics, 2015
Anja Vogt Medizinische Klinik und Poliklinik IV, Klinikum der Unversität München, Munich, Germany Abstract: Familial hypercholesterolemia (FH) results in very high levels of atherogenic low-density lipoprotein (LDL) cholesterol from the time ...
Vogt A
doaj   +1 more source

How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia? [PDF]

Journal of Atherosclerosis and Thrombosis, 2022
Yu Kataoka, Sayaka Funabashi, Mariko Harada-Shiba   +2 more
exaly   +2 more sources

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE). [PDF]

Front Cardiovasc Med, 2022
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and ...
Sudano I, Mach F, Moccetti T, Burkard T, Fahe C, Delabays A, Rickli H, Keller PF, Dopheide J, Bodenmann S, Fiolka T, Ehret G, Spirk D.   +12 more
europepmc   +3 more sources

How do index patients participating in genetic screening programmes for familial hypercholesterolemia (FH) interpret their DNA results?:A UK-based qualitative interview study [PDF]

, 2011
OBJECTIVE: To explore patients' interpretations of their DNA results for familial hypercholesterolemia (FH). METHODS: In-depth interviews were conducted with patients from two lipid clinics in Scotland, who were offered genetic testing as part of a ...
Jenkins, Nick, Lawton, Julia, Douglas, Margaret, Walker, Simon, Hallowell, Nina, Finnie, Robert, Porteous, Mary   +6 more
core   +1 more source

Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing:a population-based study [PDF]

, 2014
BACKGROUND: Familial hypercholesterolaemia (FH) is a common Mendelian condition which, untreated, results in premature coronary heart disease. An estimated 88% of FH cases are undiagnosed in the UK.
Soutar, Anne K., Shona M Kerr, Jennifer Biggs, Anne K Soutar, Aitman, Timothy J., Porteous, David J, Morris, Andrew D., Morris, Andrew D, Scotland, Generation, Blair H Smith, Generation Scotland, Smith, Blair H, Anna F Dominiczak, Thomas, Ellen, Soutar, Anne K, Vandrovcova, Jana, Kerr, Shona M, Kerr, Shona M., Archie Campbell, Biggs, Jennifer, Norsworthy, Penny J, David J Porteous, Laurence Game, Thomas, Ellen R. A., Game, Laurence, Penny J Norsworthy, Smith, Blair H., Norsworthy, Penny J., Campbell, Archie, Porteous, David J., Aitman, Timothy J, Ellen RA Thomas, Dominiczak, Anna F, Smith, Blair H.; id_orcid, Jana Vandrovcova, ?, ?, Dominiczak, Anna F., Thomas, Ellen RA, Timothy J Aitman, Andrew D Morris   +39 more
core   +2 more sources

Would raising the total cholesterol diagnostic cut-off from 7.5 mmol/L to 9.3 mmol/L improve detection rate of patients with monogenic familial hypercholesterolaemia? [PDF]

, 2015
A previous report suggested that 88% of individuals in the general population with total cholesterol (TC) > 9.3 mmol/L have familial hypercholesterolaemia (FH). We tested this hypothesis in a cohort of 4896 UK civil servants, mean (SD) age 44 (±6) years,
Humphries, S.E., Kivimaki, M, Boustred, C, Boustred, C., Kumari, M., Kivimaki, M., Humphries, SE, Futema, M., Futema, M, Kumari, M   +9 more
core   +1 more source